NEW YORK (GenomeWeb News) – 3M has entered into a joint development and licensing deal for use of Lumora's BART technology in developing nucleic acid test kits, the firms announced today.
Financial and other details of the agreement were not disclosed.
BART, which stands for Bioluminescent Assay in Real-Time, is a novel reporter system for use with isothermal nucleic acid amplification technologies as a tool in molecular diagnostics. In a statement, UK-based Lumora said that it is looking for other collaborative development and licensing partnerships "to bring its core technology to market in industrial sectors and clinical in vitro diagnostic applications."
In May the company announced it had raised about $2.1 million in second-stage funding, which would be used to accelerate its move in the clinical molecular diagnostics space with the BART technology.